ARK Investment Management LLC Has $226.15 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

ARK Investment Management LLC boosted its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 35.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,041,287 shares of the company's stock after acquiring an additional 1,047,827 shares during the quarter. 10x Genomics accounts for about 1.3% of ARK Investment Management LLC's holdings, making the stock its 22nd biggest holding. ARK Investment Management LLC owned 3.42% of 10x Genomics worth $226,150,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James & Associates lifted its stake in 10x Genomics by 19.3% during the first quarter. Raymond James & Associates now owns 53,009 shares of the company's stock worth $4,032,000 after purchasing an additional 8,570 shares during the last quarter. US Bancorp DE lifted its position in shares of 10x Genomics by 39.6% during the 1st quarter. US Bancorp DE now owns 9,711 shares of the company's stock worth $739,000 after buying an additional 2,753 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of 10x Genomics by 617.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,046 shares of the company's stock valued at $155,000 after buying an additional 1,761 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in 10x Genomics during the 1st quarter worth $416,000. Finally, BlackRock Inc. lifted its position in 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company's stock valued at $696,572,000 after acquiring an additional 1,138,358 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

Insider Activity at 10x Genomics

In other news, CEO Serge Saxonov sold 1,000 shares of the company's stock in a transaction on Friday, February 9th. The stock was sold at an average price of $49.53, for a total value of $49,530.00. Following the sale, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Serge Saxonov sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $49.53, for a total transaction of $49,530.00. Following the sale, the chief executive officer now owns 855,381 shares in the company, valued at $42,367,020.93. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Justin J. Mcanear sold 1,865 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $86,424.10. Following the transaction, the chief financial officer now directly owns 95,240 shares in the company, valued at approximately $4,413,421.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,959 shares of company stock valued at $773,766. Insiders own 10.65% of the company's stock.

10x Genomics Stock Performance

NASDAQ:TXG traded up $0.64 during trading hours on Thursday, hitting $37.53. The company's stock had a trading volume of 1,410,260 shares, compared to its average volume of 1,430,911. 10x Genomics, Inc. has a 52-week low of $33.79 and a 52-week high of $63.57. The business's 50-day moving average is $42.97 and its two-hundred day moving average is $44.11. The company has a market capitalization of $4.47 billion, a PE ratio of -17.29 and a beta of 1.93.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.05). The company had revenue of $183.98 million for the quarter, compared to analysts' expectations of $182.73 million. 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The firm's quarterly revenue was up 17.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.15) EPS. As a group, analysts predict that 10x Genomics, Inc. will post -1.47 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on TXG. Guggenheim began coverage on 10x Genomics in a research report on Thursday, December 14th. They issued a "buy" rating and a $60.00 target price for the company. Barclays raised their price objective on shares of 10x Genomics from $45.00 to $55.00 and gave the stock an "overweight" rating in a research report on Thursday, January 25th. Stifel Nicolaus reduced their target price on shares of 10x Genomics from $68.00 to $63.00 and set a "buy" rating for the company in a report on Friday, February 16th. Bank of America upgraded 10x Genomics from an "underperform" rating to a "neutral" rating and boosted their price target for the company from $36.00 to $54.00 in a research report on Tuesday, December 12th. Finally, Wolfe Research began coverage on 10x Genomics in a research note on Wednesday, December 13th. They issued an "outperform" rating and a $55.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $62.44.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.